NeOnc Technologies Holdings Inc(NTHI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:12 PM ET (Korea 11/7 06:12)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.95 | Insider Own | 90.84% | Shs Outstand | 27.8M | Perf Week | 7.06% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 24.19% | Insider Trans | 0.66% | Shs Float | 2.6M | Perf Month | 37.94% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.26 | Inst Own | 10.96% | Short Float | 33.21% | Perf Quarter | -0.29% |
| Income | -0.05B | P/S | - | EPS this Y | 57.63% | Inst Trans | 1.86% | Short Ratio | 4.15 | Perf Half Y | -35.96% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 32.48% | ROA | -642.77% | Short Interest | 0.88M | Perf YTD | -57.8% |
| Book/sh | -0.47 | P/C | 16.29 | EPS past 3/5Y | -176.88% -109.2% | ROE | - | 52W High | -70.92% ($12.00) | Perf Year | -64.57% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | 25.98% - | ROIC | - | 52W Low | 39.54% ($2.50) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 33.59% | Gross Margin | - | Volatility(W/M) | 10.28% 10.17% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.31 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | 37.1% | Profit Margin | - | RSI (14) | 59.94 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.34 | Sales Q/Q | - | SMA20 | 17.76% ($2.96) | Beta | 0.88 | Target Price | $17 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | 4.71% ($3.33) | Rel Volume | 1.08 | Prev Close | $3.2 |
| Employees | 5 | LT Debt/Eq | - | EPS/Sales Surpr. | -12.9% - | SMA200 | -34.59% ($5.34) | Avg Volume(3M) | 0.21M | Price | $3.49 |
| IPO | 2025/3/26 | Option/Short | No/Yes | Trades | 744 | Volume | 228,039 | Change | 9.06% |
🧠 Neonode Technologies is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including brain tumors. The company focuses on candidates that target the blood-brain barrier, which is notoriously difficult for drugs to cross, and is pursuing novel approaches in hard-to-treat areas such as primary brain cancer. Its valuation is heavily dependent on progress in its clinical pipeline rather than commercialized products.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded about as much as usual. That is 108% of its average volume.
NTHI has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +57.6% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
33.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #355 of 597 in the industry
Based on market cap of $101M.
HURA#353 TuHURA Biosciences Inc $104M PER - 
NRXP#354 NRX Pharmaceuticals Inc $103M PER - NTHI#355 NeOnc Technologies Holdings Inc $101M PER - 
BDTX#356 Black Diamond Therapeutics Inc $100M PER - 
UNCY#357 Unicycive Therapeutics Inc $99M PER - 
FAQ
What kind of company is NTHI?
NTHI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NTHI?
The market cap of NTHI is approximately $101M, ranking 4,481 within its sector.
What is the 52-week high and low for NTHI?
NTHI has recorded a 52-week high of $12.00 and a low of $2.50.
